You are here

News

August 24, 2015
New Ebola vaccine study begins in Nigeria

The vaccine used in the study (RV429) is the monovalent chimpanzee adenovirus Type 3 (ChAd3) candidate developed at the NIAID and being developed by GlaxoSmithKline (GSK), the study sponsor. First vaccinations began on 21 August.

Since 2005, MHRP’s program in Nigeria—called the Walter Reed Program-Nigeria—has been working closely with the Nigerian Ministries of Defence and Health to...

August 19, 2015
MHRP study indicates increase in HIV subtypes in Kenya

Recent analysis of data from Kenya shows a rise in both the number and complexity of inter-subtype recombinants of HIV-1, which could pose a significant challenge for vaccine development.

In a new paper published today in PLOS One, researchers led by MHRP analyzed the molecular epidemiology of HIV-1 subtypes within a tea plantation community cohort in Kenya.

In June 2003, MHRP...

July 23, 2015
MHRP Welcomes Lydie Trautmann, Chief of Cellular Immunology

Dr. Trautmann joins the program after more than five years with the Vaccine & Gene Therapy Institute of Florida where she collaborated on acute HIV infection research with Dr. Jintanat Ananworanich. She says she was inspired to join MHRP by the chance to work more closely with these unique acute cohorts.

  “Human immunology is hard. You need to work with strong cohorts in order to...

July 17, 2015
Researchers find multiple co-circulating HIV-1 subtypes in North Africa and Middle East

Noting a lack of HIV epidemiology research focused specifically on North Africa and the Middle East, MHRP researchers Morgane Rolland and Kayvon Modjarrad, conducted an analysis of publicly available HIV-1 sequences to better characterize the regional epidemic. 

The results were published in a research letter today in the journal AIDS.  Their analysis suggests a complicated and diverse...

July 15, 2015
Host Genetics Played a Role in RV144 Protection

Researchers at the U.S. Military HIV Research Program (MHRP) tested whether specific variants of immune response genes called HLA were associated with greater protection against the virus. 

“We found that antibody responses correlated with increased or decreased risk of acquiring HIV only in the presence of specific host HLA alleles,” said senior author Dr. Rasmi Thomas.  By identifying...

June 3, 2015
Humanized DRAG Mouse Model Holds Promise For Pre-Clinical Testing of Candidate HIV Vaccines

A new study led by MHRP researchers in collaboration with the Military Malaria Vaccine Program shows that T follicular helper cells (Tfh) accumulate in the gut and female reproductive tract of humanized DRAG mice, which are highly permissive to HIV infection. Researchers believe this will provide a new pre-clinical model to understand the early events in mucosal HIV infection and help to...

May 18, 2015
MHRP Marks HIV Vaccine Awareness Day

The 2014 Ebola outbreak in West Africa is a stark reminder of the constant threat infectious diseases pose to communities around the world, including  the U.S. Military. If we’d had an effective vaccine against Ebola, much of the pain, suffering and death could have been avoided. 

This experience serves as a reminder of the power of vaccines, which have dramatically reduced the impact...

April 22, 2015
Long-term Adverse Health Effects of Ebola Survivors Examined in New Lancet ID Paper

Survivors of the 2007-08 Bundibugyo ebolavirus (BDBV) outbreak in Uganda experienced negative health effects that persisted more than two years after the outbreak claimed 39 lives, according to findings from an MHRP study published in The Lancet Infectious Diseases today. 

The study represents the largest long-term study to-date on Ebola survivors, and examines health events more than...

April 20, 2015
MHRP Researchers Provide Insight into Worlds Most Potent Vaccine Adjuvant

In a new paper titled, “Detection of liposomal cholesterol and monophosphoryl lipid A by QS-21 saponin and Limulus polyphemus amebocyte lysate,” MHRP researcher and liposome pioneer Dr. Carl Alving and his team deconstruct the underlying science behind the physical structure of the world’s most potent vaccine adjuvant. 

The paper, published in the March issue of the journal, BBA...

April 1, 2015
Findings from WRAIR-NIAID EBOV Clinical Trial Published in NEJM

Findings from a WRAIR/NIAID led Ebola vaccine clinical trail were published in the New England Journal of Medicine today, highlighting that the vaccine candidate is safe and elicits a robust immune response.  The VSV-EBOV candidate was tested in a small phase 1 clinical trial that explored the safety and immunogeniticy of the vaccine when administered at different doses. MHRP's Diagnostics...

Pages